

Hidekazu Suzuki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4241676/publications.pdf>

Version: 2024-02-01

194
papers

11,063
citations

76326
40
h-index

32842
100
g-index

216
all docs

216
docs citations

216
times ranked

19170
citing authors

#	ARTICLE	IF	CITATIONS
1	Experimental and translational research in gastrointestinal endoscopy, the Japan Gastroenterological Endoscopy Society and perspective. Digestive Endoscopy, 2022, 34, 129-131.	2.3	0
2	Is active exercise effective in preventing metachronous advanced colorectal neoplasm after polypectomy?. Digestive Endoscopy, 2022, 34, 838-839.	2.3	0
3	Decreased anti-parietal cell antibody titer in the advanced phase of autoimmune gastritis. Scandinavian Journal of Gastroenterology, 2022, 57, 143-148.	1.5	10
4	A Questionnaire-Based Survey on the Impact of the COVID-19 Pandemic on Gastrointestinal Endoscopy in Asia. Digestion, 2022, 103, 7-21.	2.3	9
5	Development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after <i>Helicobacter pylori</i> eradication. Annals of Medicine, 2022, 54, 170-180.	3.8	5
6	Response to letter regarding: development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after <i>Helicobacter pylori</i> eradication. Annals of Medicine, 2022, 54, 856-857.	3.8	0
7	TXI (Texture and Color Enhancement Imaging) for Serrated Colorectal Lesions. Journal of Clinical Medicine, 2022, 11, 119.	2.4	13
8	Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line <i>Helicobacter pylori</i> eradication regimen. Helicobacter, 2022, 27, .	3.5	9
9	Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next?. United European Gastroenterology Journal, 2021, 9, 7-8.	3.8	1
10	Herbal medicines in functional dyspepsia—Untapped opportunities not without risks. Neurogastroenterology and Motility, 2021, 33, e14044.	3.0	11
11	Prevalence of the pathobiont adherent-invasive <i>Escherichia coli</i> and inflammatory bowel disease: a systematic review and meta-analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 852-863.	2.8	44
12	Magnesium Oxide in Constipation. Nutrients, 2021, 13, 421.	4.1	29
13	Precision Medicine Approaches to Prevent Gastric Cancer. Gut and Liver, 2021, 15, 3-12.	2.9	29
14	Oxidative stress in stomach cancer. , 2021, , 49-54.		0
15	Celiac Disease Complicated by Rhabdomyolysis. Internal Medicine, 2021, 60, 217-222.	0.7	2
16	Recent Advances in the Definition and Management of Functional Dyspepsia. Keio Journal of Medicine, 2021, 70, 7-18.	1.1	7
17	The simplified Kyoto classification score is consistent with the ABC method of classification as a grading system for endoscopic gastritis. Journal of Clinical Biochemistry and Nutrition, 2021, 68, 101-104.	1.4	10
18	Risk Factors for Prolonged Hospital Stay after Endoscopy. Clinical Endoscopy, 2021, 54, 851-856.	1.5	2

#	ARTICLE	IF	CITATIONS
19	Editorial: An important milestone for systematizing gastroparesis practice. United European Gastroenterology Journal, 2021, 9, 285-286.	3.8	2
20	The gastrointestinal tract in hunger and satiety signalling. United European Gastroenterology Journal, 2021, 9, 727-734.	3.8	27
21	Sitafloxacin for Third-Line Helicobacter pylori Eradication: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 2722.	2.4	11
22	Clue of Diagnosis for Autoimmune Gastritis. Digestion, 2021, 102, 903-910.	2.3	10
23	Intraoperative Endoscopy in Transient Adult Jejunojunal Intussusception. Case Reports in Gastrointestinal Medicine, 2021, 2021, 1-6.	0.3	0
24	Three Cases of Esophageal Cancer Related to Fanconi Anemia. Internal Medicine, 2021, 60, 2953-2959.	0.7	2
25	Sedation for Endoscopic Ultrasound. , 2021, , 217-222.		0
26	Gastric Cancer Screening System to Achieve Eradication of Gastric Cancer. Health Evaluation and Promotion, 2021, 48, 407-412.	0.0	0
27	10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy. Digestion, 2020, 101, 644-650.	2.3	12
28	Complete closure versus simple closure for perforations during colorectal endoscopic submucosal dissection. Endoscopy International Open, 2020, 08, E76-E80.	1.8	4
29	Colonoscopy using back brace support belt: A randomized, prospective trial. JGH Open, 2020, 4, 441-445.	1.6	7
30	Effects of Encircled Abdominal Compression Device in Colonoscopy: A Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 11.	2.4	19
31	<p>Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease</p>Journal of Inflammation Research, 2020, Volume 13, 563-570.	3.5	9
32	The Impact of COVID-19 on Gastrointestinal Motility Testing in Asia and Europe. Journal of Clinical Medicine, 2020, 9, 3189.	2.4	4
33	Short-chain fatty acids bind to apoptosis-associated speck-like protein to activate inflammasome complex to prevent Salmonella infection. PLoS Biology, 2020, 18, e3000813.	5.6	32
34	Long-Term Outcomes of Endoscopic Submucosal Dissection for Superficial Esophageal Squamous Cell Carcinoma. Cancers, 2020, 12, 2849.	3.7	19
35	Helicobacter pylori eradication improved the Kyoto classification score on endoscopy. JGH Open, 2020, 4, 909-914.	1.6	15
36	PCR analysis and specific immunohistochemistry revealing a high prevalence of non- <i>Helicobacter pylori</i> Helicobacters in <i>Helicobacter pylori</i> -negative gastric disease patients in Japan: High susceptibility to an Hp eradication regimen. Helicobacter, 2020, 25, e12700.	3.5	33

#	ARTICLE	IF	CITATIONS
37	Additional Mosapride to Proton Pump Inhibitor for Gastroesophageal Reflux Disease: A Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 2705.	2.4	3
38	Nodularity-like appearance in the cardia: novel endoscopic findings for Helicobacter pylori infection. Endoscopy International Open, 2020, 08, E770-E774.	1.8	13
39	A survey on the impact of the COVID-19 pandemic on motility and functional investigations in Europe and considerations for recommencing activities in the early recovery phase. Neurogastroenterology and Motility, 2020, 32, e13926.	3.0	14
40	<p>>Sugar Codes Conjugated Alginate: An Innovative Platform to Make a Strategic Breakthrough in Simultaneous Prophylaxis of GERD and >Helicobacter pylori> Infection</p>>. Drug Design, Development and Therapy, 2020, Volume 14, 2405-2412.	4.3	1
41	Adverse events associated with bidirectional endoscopy with midazolam and pethidine. Journal of Clinical Biochemistry and Nutrition, 2020, 66, 78-81.	1.4	7
42	The Role of GI Peptides in Functional Dyspepsia and Gastroparesis: A Systematic Review. Frontiers in Psychiatry, 2020, 11, 172.	2.6	30
43	Statements for conducting high-resolution manometry during the COVID-19 pandemic. Journal of Clinical Biochemistry and Nutrition, 2020, 67, 114-115.	1.4	2
44	Update on quinolone-containing rescue therapies for <i>Helicobacter pylori</i> infection. World Journal of Gastroenterology, 2020, 26, 1733-1744.	3.3	14
45	Endoscopy-based Kyoto classification score of gastritis related to pathological topography of neutrophil activity. World Journal of Gastroenterology, 2020, 26, 5146-5155.	3.3	11
46	Helicobacter suis Infection in Mouse Induced not Only Gastric, but Hepatic and Pulmonary MALT Lymphoma: Relation to Substance P. Current Pharmaceutical Design, 2020, 26, 3039-3045.	1.9	1
47	Clinical features of cardiac nodularity-like appearance induced by <i>Helicobacter pylori</i> infection. World Journal of Gastroenterology, 2020, 26, 5354-5361.	3.3	6
48	Title is missing!. , 2020, 18, e3000813.		0
49	Title is missing!. , 2020, 18, e3000813.		0
50	Title is missing!. , 2020, 18, e3000813.		0
51	Title is missing!. , 2020, 18, e3000813.		0
52	Title is missing!. , 2020, 18, e3000813.		0
53	Title is missing!. , 2020, 18, e3000813.		0
54	Clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide. Journal of Clinical Biochemistry and Nutrition, 2019, 65, 76-81.	1.4	23

#	ARTICLE	IF	CITATIONS
55	How to select patients for antireflux surgery? The ICARUS guidelines (international consensus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 12.1 80		
56	Current status of first- and second-line <i>Helicobacter pylori</i> eradication therapy in the metropolitan area: a multicenter study with a large number of patients. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481985851.	3.2	30
57	Neutrophil-activating Protein Polymorphism of <i>Helicobacter pylori</i> Determines the Host Risk of Dyspepsia. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 295-297.e6.	4.5	6
58	Cancer Stem-Cell Marker CD44v9-Positive Cells Arise From <i>Helicobacter pylori</i> -Infected CAPZA1-Overexpressing Cells. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 319-334.	4.5	28
59	Guidelines for the management of <i>Helicobacter pylori</i> infection in Japan: 2016 Revised Edition. Helicobacter, 2019, 24, e12597.	3.5	189
60	Clinical and endoscopic findings to assist the early detection of duodenal adenoma and adenocarcinoma. United European Gastroenterology Journal, 2019, 7, 250-260.	3.8	5
61	A combination of serum anti- <i>Helicobacter pylori</i> antibody titer and Kyoto classification score could provide a more accurate diagnosis of H pylori. United European Gastroenterology Journal, 2019, 7, 343-348.	3.8	22
62	High Prevalence of Antibiotic Resistance in Iranian <i>Helicobacter pylori</i> Isolates: Importance of Functional and Mutational Analysis of Resistance Genes and Virulence Genotyping. Journal of Clinical Medicine, 2019, 8, 2004.	2.4	36
63	To establish a treatment for GI symptoms of cystic fibrosis, it is necessary to develop a symptom evaluation tool. United European Gastroenterology Journal, 2019, 7, 873-874.	3.8	1
64	CAPZA1 determines the risk of gastric carcinogenesis by inhibiting <i>Helicobacter pylori</i> CagA-degraded autophagy. Autophagy, 2019, 15, 242-258.	9.1	36
65	The novel de novo mutation of KIF1A gene as the cause for Spastic paraplegia 30 in a Japanese case. ENeurologicalSci, 2019, 14, 34-37.	1.3	18
66	Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. Journal of Neurogastroenterology and Motility, 2019, 25, 6-14.	2.4	53
67	Changes of gastric ulcer bleeding in the metropolitan area of Japan. World Journal of Gastroenterology, 2019, 25, 6342-6353.	3.3	13
68	Reply to the letter to the editor: H. pylori test-and-treat should not be put off for gastric cancer prevention in East Asia any longer. Journal of Gastroenterology, 2018, 53, 789-790.	5.1	0
69	Gastric cancer: evidence boosts <i>Helicobacter pylori</i> eradication. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 458-460.	17.8	19
70	Diagnosis of Parkinson's disease and the level of oxidized DJ-1 protein. Neuroscience Research, 2018, 128, 58-62.	1.9	15
71	<i>Helicobacter pylori</i> eradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk. Gut, 2018, 67, 2071-2072.	12.1	10
72	World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. Journal of Gastroenterology, 2018, 53, 354-361.	5.1	100

#	ARTICLE	IF	CITATIONS
73	Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression. <i>Anticancer Research</i> , 2018, 38, 6163-6170.	1.1	43
74	Autotaxin and vascular endothelial growth factor receptor α 2 and α 3 are related to vascular development during the progression of chronic viral hepatitis C. <i>Apmis</i> , 2018, 126, 913-921.	2.0	3
75	Feasibility of endoscopic mucosa-submucosa clip closure method (with video). <i>Endoscopy International Open</i> , 2018, 06, E1070-E1074.	1.8	11
76	Pethidine dose and female sex as risk factors for nausea after esophagogastroduodenoscopy. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2018, 63, 230-232.	1.4	10
77	Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test. <i>Journal of Neurogastroenterology and Motility</i> , 2018, 24, 577-583.	2.4	8
78	Serum Autotaxin Concentrations Reflect Changes in Liver Stiffness and Fibrosis After Antiviral Therapy in Patients with Chronic Hepatitis C. <i>Hepatology Communications</i> , 2018, 2, 1111-1122.	4.3	9
79	Acquisition of double mutation in <i>gyrA</i> caused high resistance to sitafloxacin in <i>Helicobacter pylori</i> after unsuccessful eradication with sitafloxacin-containing regimens. <i>United European Gastroenterology Journal</i> , 2018, 6, 391-397.	3.8	21
80	Propofol for gastrointestinal endoscopy. <i>United European Gastroenterology Journal</i> , 2018, 6, 801-805.	3.8	54
81	Introduction to serial reviews: Oxidative stress and digestive diseases. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2018, 63, 5-5.	1.4	2
82	<i>Helicobacter pylori</i> infection in subjects negative for high titer serum antibody. <i>World Journal of Gastroenterology</i> , 2018, 24, 1419-1428.	3.3	40
83	Family history is an independent risk factor for the progression of gastric atrophy among patients with <i>Helicobacter pylori</i> infection. <i>United European Gastroenterology Journal</i> , 2017, 5, 32-36.	3.8	25
84	Prevalence of Gastric Non- <i>Helicobacter pylori</i> - <i>Helicobacters</i> in Japanese Patients with Gastric Disease. <i>Digestion</i> , 2017, 95, 61-66.	2.3	24
85	<i>Helicobacter pylori</i> -Associated Upper Gastrointestinal Symptoms: FD or HpD?. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1391-1393.	2.3	3
86	Effect of prophylactic clipping in colorectal endoscopic resection: A meta-analysis of randomized controlled studies. <i>United European Gastroenterology Journal</i> , 2017, 5, 859-867.	3.8	46
87	Antibiotic resistance and <i>gyrA</i> mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for <i>Helicobacter pylori</i> in penicillin allergic patients. <i>United European Gastroenterology Journal</i> , 2017, 5, 796-804.	3.8	17
88	Markers for Guillain-Barré syndrome with poor prognosis: a multicenter study. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 433-439.	3.1	46
89	Gender Difference of Gastric Emptying in Healthy Volunteers and Patients with Functional Dyspepsia. <i>Digestion</i> , 2017, 95, 72-78.	2.3	44
90	Dexmedetomidine vs propofol for gastrointestinal endoscopy: A meta-analysis. <i>United European Gastroenterology Journal</i> , 2017, 5, 1037-1045.	3.8	43

#	ARTICLE	IF	CITATIONS
91	Effects of patient age and choice of antisecretory agent on success of eradication therapy for <i>Helicobacter pylori</i> infection. Journal of Clinical Biochemistry and Nutrition, 2017, 60, 208-210.	1.4	34
92	Circulating microRNAs as potential biomarkers to detect transformation of Barrett's oesophagus to oesophageal adenocarcinoma. BMJ Open Gastroenterology, 2017, 4, e000160.	2.7	11
93	Bile Acids and Esophageal Cancer. , 2017, , 177-184.		1
94	Characteristics of gastric cancer detected within 1 year after successful eradication of <i>Helicobacter pylori</i> . Journal of Clinical Biochemistry and Nutrition, 2016, 59, 226-230.	1.4	27
95	Different Pathophysiology of Gastritis between East and West? An Asian Perspective. Inflammatory Intestinal Diseases, 2016, 1, 123-128.	1.9	24
96	Profile of acotiamide in the treatment of functional dyspepsia. Clinical and Experimental Gastroenterology, 2016, 9, 83.	2.3	14
97	Association of baseline plasma desacyl ghrelin level with the response to rikkunshito in patients with functional dyspepsia. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 334-341.	2.8	24
98	Efficacy of 10-day Sitafloracin-Containing Third-Line Rescue Therapies for <i>Helicobacter pylori</i> Strains Containing the <i>gyrA</i> Mutation. Helicobacter, 2016, 21, 286-294.	3.5	33
99	Functional Dyspepsia: Pathogenesis, Diagnosis, and Treatment. Journal of General and Family Medicine, 2016, 17, 204-210.	0.8	5
100	Timing of oral refeeding in acute pancreatitis: A systematic review and meta-analysis. United European Gastroenterology Journal, 2016, 4, 725-732.	3.8	27
101	Gastrointestinal Disorders. Gastroenterology, 2016, 150, 1380-1392.	1.3	1,088
102	Reply to letter to the editor: "The dosage of rifabutin in H. pylori eradication regimen should be appropriately determined in each area of the world". United European Gastroenterology Journal, 2016, 4, 476-477.	3.8	1
103	Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for <i>Helicobacter pylori</i> eradication: A pilot study. United European Gastroenterology Journal, 2016, 4, 380-387.	3.8	40
104	Questionnaire-Based Survey on Diagnostic and Therapeutic Endoscopies and <i>H. pylori</i> Eradication for Elderly Patients in East Asian Countries. Digestion, 2016, 93, 93-102.	2.3	7
105	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
106	Effects of preoperative proton pump inhibitor administration on bleeding after gastric endoscopic submucosal dissection: A systematic review and meta-analysis. United European Gastroenterology Journal, 2016, 4, 5-10.	3.8	18
107	Effects of carbon dioxide insufflation in balloon-assisted enteroscopy: A systematic review and meta-analysis. United European Gastroenterology Journal, 2016, 4, 11-17.	3.8	17
108	Clarithromycin Versus Metronidazole as First-line <i>Helicobacter pylori</i> Eradication. Journal of Clinical Gastroenterology, 2015, 49, 468-471.	2.2	62

#	ARTICLE	IF	CITATIONS
109	Role of MicroRNAs-221/222 in Digestive Systems. Journal of Clinical Medicine, 2015, 4, 1566-1577.	2.4	35
110	Association of Visceral Fat Area, Smoking, and Alcohol Consumption with Reflux Esophagitis and Barrett's Esophagus in Japan. PLoS ONE, 2015, 10, e0133865.	2.5	47
111	Gastric Carcinogenesis and Underlying Molecular Mechanisms: <i>Helicobacter pylori</i> and Novel Targeted Therapy. BioMed Research International, 2015, 2015, 1-7.	1.9	30
112	<i>Helicobacter pylori</i> and Pathogenesis. BioMed Research International, 2015, 2015, 1-2.	1.9	3
113	Nordihydroguaiaretic Acid Disrupts the Antioxidant Ability of <i>Helicobacter pylori</i> through the Repression of SodB Activity In Vitro. BioMed Research International, 2015, 2015, 1-8.	1.9	8
114	Second-look endoscopy after endoscopic submucosal dissection for gastric neoplasms. Digestive Endoscopy, 2015, 27, 279-284.	2.3	23
115	Evidence-based clinical practice guidelines for functional dyspepsia. Journal of Gastroenterology, 2015, 50, 125-139.	5.1	145
116	Dexmedetomidine versus midazolam for gastrointestinal endoscopy: A meta-analysis. Digestive Endoscopy, 2015, 27, 8-15.	2.3	44
117	<i>Helicobacter pylori</i> gastritis is a novel distinct disease entity. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 556-557.	17.8	37
118	The "Two-Sword Fencing" Technique in Endoscopic Submucosal Dissection. Clinical Endoscopy, 2015, 48, 85.	1.5	5
119	Mechanisms of <i>Helicobacter pylori</i> antibiotic resistance and molecular testing. Frontiers in Molecular Biosciences, 2014, 1, 19.	3.5	83
120	Effect of supplementation with rebamipide for <i>Helicobacter pylori</i> eradication therapy: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 20-24.	2.8	29
121	Changes in the first line <i>Helicobacter pylori</i> eradication rates using the triple therapy—a multicenter study in the Tokyo metropolitan area (Tokyo <i>Helicobacter</i>) Tj ETQq1 1 0.784314 rg31/Overl	2.4	31
122	Propofol versus traditional sedative agents for endoscopic submucosal dissection. Digestive Endoscopy, 2014, 26, 701-706.	2.3	26
123	Ameliorative Effect of Mepenzolate Bromide against Pulmonary Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 79-88.	2.5	13
124	Trends of Second-Line Eradication Therapy for <i>Helicobacter pylori</i> in Japan: A Multicenter Study in the Tokyo Metropolitan Area. Helicobacter, 2013, 18, 468-472.	3.5	22
125	Bile Acids Increase Levels of MicroRNAs 221 and 222, Leading to Degradation of CDX2 During Esophageal Carcinogenesis. Gastroenterology, 2013, 145, 1300-1311.	1.3	59
126	Validation of the GerdQ questionnaire for the management of gastroesophageal reflux disease in Japan. United European Gastroenterology Journal, 2013, 1, 175-183.	3.8	56

#	ARTICLE	IF	CITATIONS
127	The Role of microRNA in Gastric Malignancy. International Journal of Molecular Sciences, 2013, 14, 9487-9496.	4.1	29
128	Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial. United European Gastroenterology Journal, 2013, 1, 445-452.	3.8	42
129	Helicobacter pylori infection in functional dyspepsia. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 168-174.	17.8	157
130	Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapy. Journal of Clinical Biochemistry and Nutrition, 2013, 52, 172-178.	1.4	23
131	Efficacy of Sitaflaxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies. Antimicrobial Agents and Chemotherapy, 2012, 56, 1643-1645.	3.2	50
132	Reactive Oxygen Species-Induced Autophagic Degradation of Helicobacter pylori CagA Is Specifically Suppressed in Cancer Stem-like Cells. Cell Host and Microbe, 2012, 12, 764-777.	11.0	200
133	Low-density Lipoprotein Receptor-related Protein-1 (LRP1) Mediates Autophagy and Apoptosis Caused by Helicobacter pylori VacA. Journal of Biological Chemistry, 2012, 287, 31104-31115.	3.4	127
134	Development of a novel microRNA promoter microarray for ChIP-on-chip assay to identify epigenetically regulated microRNAs. Biochemical and Biophysical Research Communications, 2012, 426, 33-37.	2.1	18
135	Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial. Journal of Neurogastroenterology and Motility, 2012, 18, 317-323.	2.4	15
136	FecA1, a bacterial iron transporter, determines the survival of Helicobacter pylori in the stomach. Free Radical Biology and Medicine, 2012, 52, 1003-1010.	2.9	16
137	Molecular Approaches and Modern Clinical Strategies for the Management of Helicobacter pylori Infection in Japan. Keio Journal of Medicine, 2012, 61, 109-119.	1.1	10
138	Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction. World Journal of Gastroenterology, 2012, 18, 2735.	3.3	21
139	Enhanced bacterial efflux system is the first step to the development of metronidazole resistance in Helicobacter pylori. Biochemical and Biophysical Research Communications, 2011, 404, 656-660.	2.1	42
140	What Is the Difference Between -Associated Dyspepsia and Functional Dyspepsia?. Journal of Neurogastroenterology and Motility, 2011, 17, 124-130.	2.4	40
141	Roles of oxidative stress in stomach disorders. Journal of Clinical Biochemistry and Nutrition, 2011, 50, 35-39.	1.4	141
142	Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia?. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 42-45.	2.8	49
143	Two Amino Acids Mutation of Ferric Uptake Regulator Determines Helicobacter pylori Resistance to Metronidazole. Antioxidants and Redox Signaling, 2011, 14, 15-23.	5.4	57
144	Trainee Participation during Colonoscopy Adversely Affects Polyp and Adenoma Detection Rates. Digestion, 2011, 84, 245-246.	2.3	15

#	ARTICLE	IF	CITATIONS
145	<i>Helicobacter pylori</i> Resistance to Rifabutin in the Last 7 Years. Antimicrobial Agents and Chemotherapy, 2011, 55, 5374-5375.	3.2	38
146	Enhancement of Amoxicillin Resistance after Unsuccessful <i>Helicobacter pylori</i> Eradication. Antimicrobial Agents and Chemotherapy, 2011, 55, 3012-3014.	3.2	38
147	Contribution of efflux pumps to clarithromycin resistance in <i>Helicobacter pylori</i> . Journal of Gastroenterology and Hepatology (Australia), 2010, 25, S75-9.	2.8	91
148	Homology model of the DNA gyrase enzyme of <i>Helicobacter pylori</i> , a target of quinolone-based eradication therapy. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, S7-10.	2.8	15
149	<i>H. pylori</i> -Eradication Therapy Increases RUNX3 Expression in the Glandular Epithelial Cells in Enlarged-Fold Gastritis. Journal of Clinical Biochemistry and Nutrition, 2010, 46, 259-264.	1.4	16
150	Post-infectious Functional Dyspepsia - A Novel Disease Entity among Functional Gastrointestinal Disorders - Relation to Infection? (Neurogastroenterol Motil 2009;21:832-e56). Journal of Neurogastroenterology and Motility, 2010, 16, 97-98.	2.4	8
151	<i>Helicobacter pylori</i> eradication therapy. Future Microbiology, 2010, 5, 639-648.	2.0	94
152	Quinolone-Based Third-Line Therapy for <i>Helicobacter pylori</i> Eradication. Journal of Clinical Biochemistry and Nutrition, 2009, 44, 119-124.	1.4	49
153	Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of <i>Helicobacter pylori</i> with <i>gyrA</i> Mutation. Antimicrobial Agents and Chemotherapy, 2009, 53, 1720-1721.	3.2	60
154	Early <i>Helicobacter pylori</i> Eradication Restores Sonic Hedgehog Expression in the Gastric Mucosa of Mongolian Gerbils. Digestion, 2009, 79, 99-108.	2.3	30
155	Past Rifampicin Dosing Determines Rifabutin Resistance of <i>Helicobacter pylori</i> . Digestion, 2009, 79, 1-4.	2.3	45
156	<i>Helicobacter pylori</i> and gastric cancer. Gastric Cancer, 2009, 12, 79-87.	5.3	96
157	The role of microRNAs in gastrointestinal cancers. Journal of Gastroenterology, 2009, 44, 18-22.	5.1	53
158	Gatifloxacin-based triple therapy as a third-line regimen for <i>Helicobacter pylori</i> eradication. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, S167-70.	2.8	26
159	Decreased levels of adiponectin in obese patients with gastroesophageal reflux evaluated by videoesophagography: Possible relationship between gastroesophageal reflux and metabolic syndrome. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, S216-21.	2.8	17
160	A strategy aimed at low risk ESD and Four days clinical pathway for superficial gastric neoplasias. Progress of Digestive Endoscopy, 2008, 73, 58-61.	0.0	0
161	Rapid Detection of Point Mutations Conferring Resistance to Fluoroquinolone in <i>gyrA</i> of <i>Helicobacter pylori</i> by Allele-Specific PCR. Journal of Clinical Microbiology, 2007, 45, 303-305.	3.9	44
162	<i>Helicobacter pylori</i> : present status and future prospects in Japan. Journal of Gastroenterology, 2007, 42, 1-15.	5.1	142

#	ARTICLE	IF	CITATIONS
163	Efficacy of Metronidazole as Second-Line Drug for the Treatment of <i>Helicobacter pylori</i> Infection in the Japanese Population: A Multicenter Study in the Tokyo Metropolitan Area. <i>Helicobacter</i> , 2006, 11, 152-158.	3.5	38
164	Gatifloxacin Resistance and Mutations in <i>gyrA</i> after Unsuccessful <i>Helicobacter pylori</i> Eradication in Japan. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1538-1540.	3.2	54
165	Improvement of gastrointestinal quality of life scores in cases of <i>Helicobacter pylori</i> -positive functional dyspepsia after successful eradication therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1652-1660.	2.8	57
166	Lansoprazole promotes gastric mucosal cell proliferation and migration by activating p44/p42 mitogen-activated protein kinase. <i>Wound Repair and Regeneration</i> , 2004, 12, 93-99.	3.0	19
167	A case of early stage gastric cancer spreading to the pyloric ring resected endoscopically. <i>Progress of Digestive Endoscopy</i> , 2004, 64, 70-71.	0.0	0
168	Usefulness of argon plasma coagulation using a double channel endoscope. <i>Progress of Digestive Endoscopy</i> , 2004, 64, 46-47.	0.0	0
169	Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio—a possible novel and non-invasive marker for gastric atrophy. <i>Hepato-Gastroenterology</i> , 2004, 51, 1249-54.	0.5	26
170	Rabeprazole treatment attenuated <i>Helicobacter pylori</i> -associated gastric mucosal lesion formation in Mongolian gerbils. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 787-795.	2.8	14
171	Procedure of endoscopic hemostasis using a distal attachment and short clips against upper gastrointestinal bleeding. <i>Progress of Digestive Endoscopy</i> , 2003, 63, 26-28.	0.0	1
172	Protective role of adrenal glucocorticoids for gastric mucosa in spontaneously hypertensive rats. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 376-383.	2.8	8
173	Attenuated apoptosis in <i>H. pylori</i> -colonized gastric mucosa of Mongolian gerbils in comparison with mice. <i>Digestive Diseases and Sciences</i> , 2002, 47, 90-99.	2.3	26
174	Gastric mucosal response to <i>Helicobacter pylori</i> . <i>Keio Journal of Medicine</i> , 2002, 51, 40-44.	1.1	14
175	Fatty Acids Enhance GRO/CINC-1 and Interleukin-6 Production in Rat Intestinal Epithelial Cells. <i>Journal of Nutrition</i> , 2001, 131, 2943-2950.	2.9	46
176	Chronic ethanol consumption exacerbates microcirculatory damage in rat mesentery after reperfusion. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 280, G939-G948.	3.4	44
177	Loading of mechanical pressure activates mitogen-activated protein kinase and early immediate gene in intestinal epithelial cells. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1993-2003.	2.3	15
178	Alcohol Dehydrogenase Activities in the Human Gastric Mucosa: Effects of <i>Helicobacter pylori</i> Infection, Sex, Age, and the Part of the Stomach. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 29S-34S.	2.4	10
179	Alcohol Dehydrogenase Activities in the Human Gastric Mucosa: Effects of <i>Helicobacter pylori</i> Infection, Sex, Age, and the Part of the Stomach. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 29S-34S.	2.4	7
180	Role of apoptosis in <i>Helicobacter pylori</i> -associated gastric mucosal injury. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 46-54.	2.8	31

#	ARTICLE	IF	CITATIONS
181	Omeprazole attenuates neutrophil-endothelial cell adhesive interaction induced by extracts of <i>Helicobacter pylori</i> . <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999, 14, 27-31.	2.8	29
182	Carbon monoxide-mediated alterations in paracellular permeability and vesicular transport in acetaminophen-treated perfused rat liver. <i>Hepatology</i> , 1999, 30, 160-168.	7.3	29
183	Augmented levels of gastric mucosal leucocyte activation by infection with cagA gene-positive <i>Helicobacter pylori</i> . <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 294-300.	2.8	31
184	Enhanced levels of C-X-C chemokine, human GRO α , in <i>Helicobacter pylori</i> -associated gastric disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 516-520.	2.8	33
185	Catalase and Superoxide Dismutase Secreted from <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 1997, 2, 100-105.	3.5	37
186	Effect of lipopolysaccharides on erythrocyte flow velocity in rat liver. <i>Journal of Gastroenterology</i> , 1997, 32, 783-790.	5.1	14
187	IL-1 is an important mediator for microcirculatory changes in endotoxin-induced intestinal mucosal damage. <i>Digestive Diseases and Sciences</i> , 1996, 41, 2482-2492.	2.3	19
188	Sulfhydryl blocker-induced colitis in the rat: Immunological changes in thymus gland and colonic mucosa. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1994, 9, 544-550.	2.8	2
189	Rat CINC/gro: a novel mediator for locomotive and secretagogue activation of neutrophils in vivo. <i>Journal of Leukocyte Biology</i> , 1994, 55, 652-657.	3.3	47
190	Acute and subacute toxicity tests of onion coat, natural colorant extracted from onion (<i>Allium</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 Issues, 1993, 38, 89-101.	2.3	8
191	Quantitative Analysis of Mesenteric Microcirculatory Disturbances Induced by Autonomic Nervous Irritation.. <i>Keio Journal of Medicine</i> , 1992, 41, 128-133.	1.1	11
192	Modifying effects of anticancer drugs adriamycin, actinomycin D, and cisplatin on α -fluorenylacetylamine-induced hepatocarcinogenesis in male ACl/N rats. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 1991, 32, 269-275.	2.3	1
193	Carcinogenicity examination of betel quid. II. Effect of vitamin A deficiency on rats fed semipurified diet containing betel nut and calcium hydroxide. <i>Nutrition and Cancer</i> , 1982, 4, 260-266.	2.0	20
194	Ultrawatersoluble Lipoprotein and Nonwatersoluble Lipoprotein in Ischemic Heart Disease. <i>The Journal of Japan Atherosclerosis Society</i> , 1981, 9, 649-653.	0.0	5